Wade Bolton joined Personal Genome Diagnostics (PGDx) in July 2019 as Vice President of the Program Management Organization, and in this capacity he participates actively in the planning and designing of programs, monitors their progress and develops back-up/recovery plans in the case of unplanned set-backs in project delivery. He also works hand-in-hand with senior management to make sure there is corporate visibility, agreement on program deliverables and within budget.
Prior to joining PGDx, Wade was Divisional Vice President of Research Development in the Hematology Division of Abbott Diagnostics. In this capacity he directed R&D, Program Management, Medical and Scientific Affairs, Clinical Affairs, Regulatory and Reagents. Previously, he served as President and CEO of Immunosite Technologies, President of the Institute for Immune Research, Vice President, Research and Development at Beckman Coulter as well as Vice President-Director of the Advanced Technology Center at Beckman Coulter.
Prior to Beckman Coulter, Wade was a member of the faculty in the Department of Human Biological Biochemistry and Genetics at the University of Texas Medical School, and held joint appointments in the Departments of Medicine and Endocrinology at Baylor College of Medicine. Dr. Bolton earned his doctorate’s degree in Cell Biology and has over 100 publications in peer-reviewed journals. His academic training, teaching, research efforts and publications are primarily focused on oncology and functional immune response.
Prior to Abbott Laboratories, Wade served as Vice President of the Institute for Immunology Research and was founder, President & CEO of ImmunoSite Technologies, LLC (IST). IST specialized in pharma services, and a primary focus of IST was to qualify, standardize, and when appropriate, automate functional assays associated with Cell-Mediated Immunity. Prior to founding IST, and as Vice President of Beckman Coulter, Wade managed and coordinated multiple sites across the US as well as internationally to conduct research, design, validation, and verification of in vitro diagnostic products in hematology, flow cytometry, immunoassay and products for medical research.